When you start a company, your goal is to create a popular and profitable product. You are decidedly not thinking about the fact that your product will get counterfeited and sent to the gray market when it does get popular. And trust me, that will happen.When I met with the American skincare brandOZNaturals® they were riding the wave of rapid growth and impressive success. The company was launched in 2013 by CEO Angela Irish with the goal of creating a range of clean, efficacious, and...
A few months ago, the government of the Russian Federation adopted Order Number 791-r, which appears to have significance for pharma serialization there. The primary deviation from the pharma serialization specification that has dictated the government pilot in Russia since early 2017 is the addition of two new data elements to the datamatrix barcode on secondary packaging. For the pilot, the datamatrix barcode contained:
Last month, GS1 US published a report on a DSCSA barcode assessment they conducted last year with two of the largest wholesale distributors in the US, AmerisourceBergen and McKesson. The goal of the assessment was to take a “snapshot” of pharmaceutical manufacturer progress toward meeting the serialization requirement of the Drug Supply Chain Security Act (DSCSA) by analyzing drug packages actually in the market.
Pharmaceutical manufacturers are working non-stop to get the serialization systems in place necessary to meet the USA DSCSA mandate going live this November, and the EU FMD mandate going live the following February of 2019. If serialization projects aren’t in full flight at this time, there is a significant chance that a manufacturer will not meet the deadline, not be compliant, and not be able to distribute products in those geographies.
President of the Russian Federation, Vladimir Putin, signed a new law the last week of December 2017 that is important for pharmaceutical manufacturers distributing products to or manufacturing in Russia. It establishes January 1, 2020 as
Last week, Systech participated in the FDA DSCSA Pubic Meeting, held in Silver Spring, MD at FDA headquarters. The meeting was two days long and was aimed at discussing the possible characteristics of the Enhanced Drug Distribution Security (EDDS) phase under the Drug Supply Chain Security Act (DSCSA) beginning in November of 2023. The meeting was broken down into four primary topics:
Systech is a member and strong supporter of GS1 Healthcare, the global group that promotes standardization in healthcare product and entity identification. On October 17, 2017 in Chicago, GS1 Healthcare held their fall Global Healthcare Conference.
Drug manufacturers who market drugs in Europe will need to begin applying unique identifiers and an anti-tampering device to their packaging by February 9, 2019. Most companies are already aware of these well-publicized requirements of the Falsified Medicines Directive (FMD) and the E.U. Delegated Regulation (EUDR). Systech offers packaging line management and serialization solutions that will allow you to easily meet these requirements. But you might not be aware of the other big requirement...